A new retraction notice in the British Journal of Cancer has withdrawn a previously published report that described antitumour activity from a recombinant polypeptide called GST-NT21MP in breast cancer. The retracted study, authored by Q. Yang, F. Zhang, Y. Ding and colleagues, had proposed that the experimental molecule worked by suppressing the CXCR4 signalling pathway, a biological system closely associated with tumour-cell migration, survival, invasion and interactions with the surrounding tissue. The notice is recorded under the title “Retraction Note: Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer” and carries a 2026 publication date.
Retraction is one of the strongest corrective actions used in scientific publishing. It indicates that a published paper should no longer be regarded as part of the reliable research record, even though the article may remain accessible for transparency and archival purposes. A retraction does not automatically establish that every experiment described in a paper was false, nor does it necessarily identify misconduct. It means that the article contains problems serious enough that its findings, methods, interpretation or overall reliability cannot be depended upon as originally presented. In the citation available for this case, the publication is identified as a retraction note, but no specific explanation for the decision is provided.
The withdrawn research focused on GST-NT21MP, described as a recombinant polypeptide. Recombinant molecules are produced using genetic engineering or related laboratory methods in which biological instructions are introduced into a host system so that the desired protein or peptide can be manufactured. The “GST” designation commonly refers to glutathione S-transferase, a protein frequently used in molecular biology as a fusion partner to improve the production, purification or detection of another peptide. In a fusion construct such as GST-NT21MP, the GST component may serve as a biochemical carrier or purification tag, while the NT21MP portion is intended to provide the biological activity under investigation. The retraction means that any therapeutic conclusions involving this construct must now be treated as unconfirmed.
The proposed mechanism centred on CXCR4, a seven-transmembrane chemokine receptor found on many types of cells, including subsets of breast cancer cells. CXCR4 responds primarily to the signalling molecule CXCL12, also known as stromal cell-derived factor 1. When CXCL12 binds to CXCR4, it can activate intracellular pathways involving G proteins, phosphoinositide 3-kinase, AKT, mitogen-activated protein kinases and calcium-dependent signals. In cancer biology, these pathways may support cell movement, resistance to stress, proliferation and communication with stromal cells in the tumour microenvironment. The CXCL12–CXCR4 axis has therefore attracted interest as a possible target for therapies designed to interfere with tumour dissemination or the establishment of cancer cells in distant organs.
Breast cancer is not a single disease but a collection of molecularly distinct malignancies. Tumours can differ in hormone-receptor status, HER2 expression, genomic alterations, immune-cell infiltration and sensitivity to treatment. CXCR4 activity may also vary between tumour subtypes and between cancer cells located in different regions of the same tumour. In laboratory research, an apparent reduction in CXCR4 signalling can be measured through changes in receptor abundance, downstream phosphorylation, chemotaxis, invasion through artificial membranes or tumour growth in animal models. Each assay answers a different question, and evidence from one experimental system cannot automatically establish that a molecule will be effective in patients. The withdrawal of this study removes one reported line of evidence concerning GST-NT21MP and CXCR4 in breast cancer.
For researchers, the retraction is particularly important because mechanistic claims can influence the direction of subsequent experiments. A paper proposing that a compound blocks CXCR4 may lead other laboratories to repeat the work, compare the compound with established CXCR4 inhibitors, examine its selectivity, or investigate whether the observed effects result from receptor inhibition rather than general toxicity. Reliable validation normally requires independent replication, appropriate negative and positive controls, confirmation that the fusion protein is correctly folded and biologically active, and careful separation of effects caused by the GST carrier from those caused by the therapeutic peptide. It also requires analytical evidence showing that the compound reaches the relevant cells at a biologically meaningful concentration.
The retraction also highlights the difference between a promising molecular mechanism and a clinically useful treatment. Blocking a receptor in cultured cancer cells does not demonstrate that a drug can safely reach a tumour in the human body. A candidate molecule must be evaluated for stability in blood, absorption, distribution, metabolism, elimination, immune reactions and potential toxicity. Protein-based or peptide-based agents can be rapidly degraded, may have difficulty crossing biological barriers and can trigger unintended interactions with other proteins. Even when a mechanism is valid, the therapeutic window—the difference between an effective dose and a harmful dose—must be established through progressively more rigorous preclinical and clinical studies.
The record is therefore best understood as a correction to the scientific literature rather than as evidence that CXCR4 is irrelevant to breast cancer. Research from many groups has investigated the receptor’s role in tumour biology, and the pathway remains a subject of experimental interest. However, the removal of a specific publication means that the claims attributed to GST-NT21MP should not be cited as established proof of antitumour efficacy or pathway inhibition. Scientists relying on the article should check the journal’s formal retraction record, review any accompanying editorial information and avoid using the withdrawn findings as a foundation for clinical recommendations, treatment decisions or claims about patient benefit.
For patients and the public, the central message is that a retracted research article should not be interpreted as evidence that GST-NT21MP is an available or validated breast-cancer therapy. The citation identifies a scientific publication and its correction status; it does not report a clinical trial, regulatory approval or demonstrated benefit in people. The case also illustrates how scientific publishing is designed to correct itself when concerns arise. Retractions can be unsettling, especially when a study appears to describe a novel treatment strategy, but openly marking unreliable work protects future research and helps prevent unverified findings from being amplified as medical fact. At present, the available record supports only the conclusion that the original report has been withdrawn and that its specific claims require independent reassessment.
Subject of Research: GST-NT21MP and the CXCR4 signalling pathway in breast cancer
Article Title: Retraction Note: Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer
Article References: Yang, Q., Zhang, F., Ding, Y. et al. Retraction Note: Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03584-x
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41416-026-03584-x
Keywords: breast cancer, GST-NT21MP, CXCR4, CXCL12, recombinant polypeptide, cancer signalling, retraction, tumour biology
Tags: biological mechanisms of tumor suppressionbreast cancer researchCXCR4 pathway inhibitionGST-NT21MP antitumor activityimpact of research retractionsmolecular targets in breast cancerrecombinant polypeptides in cancer therapyreliability of published researchretraction in scientific publishingscientific correction and retraction processestumor microenvironment interactionstumor-cell migration and invasion
